Medicine and Dentistry
Axillary Lymph Node
11%
Biological Marker
9%
Biopsy Technique
6%
Breast Cancer
100%
Breast Carcinoma
38%
Breast Tumor
12%
Cancer
5%
Cancer Cell
6%
Carcinoma
11%
Diagnosis
5%
Disease Free Survival
6%
Diseases
20%
Doxorubicin
5%
Epidermal Growth Factor Receptor 2
9%
Estrogen Receptor
17%
Gamma Urogastrone
9%
Hormone Receptor
7%
Immunohistochemistry
14%
Intraductal Carcinoma
13%
Lobular Carcinoma
5%
Lymph Node
12%
Lymph Node Metastasis
6%
Malignant Neoplasm
10%
Mastectomy
9%
Metastatic Carcinoma
21%
Neoadjuvant Chemotherapy
20%
Neoplasm
56%
Overall Survival
11%
Pathologist
5%
Primary Tumor
5%
Progesterone Receptor
9%
Radiation Therapy
7%
Recurrence Free Survival
7%
Recurrence Risk
5%
Recurrent Disease
21%
Sentinel Lymph Node
9%
Survival Rate
5%
Systemic Therapy
5%
Triple Negative Breast Cancer
11%
Tumor Cell
6%
Keyphrases
Breast
9%
Breast Cancer
38%
Breast Cancer Cells
5%
Breast Cancer Patients
11%
Breast Carcinoma
18%
Breast Reconstruction
5%
Chemotherapy
7%
Confidence Interval
5%
Disease-free Survival
5%
Ductal Carcinoma in Situ
9%
Early Breast Cancer
6%
Estrogen Receptor
10%
Human Epidermal Growth Factor Receptor 2 (HER2)
20%
Immunohistochemistry
7%
Invasive Breast Cancer
5%
Invasive Breast Carcinoma
5%
Locoregional Recurrence
8%
Mastectomy
6%
Metastasis
8%
Metastatic Breast Cancer
9%
Neoadjuvant Chemotherapy
15%
Nuclear Grade
6%
Overall Survival
8%
Pathological Complete Response
10%
Patients with Breast Cancer
6%
Primary Breast Cancer
6%
Primary Tumor
5%
Progesterone Receptor
5%
Prognostic Factors
6%
Prognostic Significance
6%
Trastuzumab
5%
Triple-negative Breast Cancer
10%
Tumor
24%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
19%
Carcinogenesis
6%
Epidermal Growth Factor Receptor
6%
Estrogen Receptor
12%
Gene Expression
5%
Genomics
7%
Hormone Receptor
6%
Progesterone Receptor
6%
Tumor Progression
5%